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TaSkin toxicities are themost common side effects associatedwith the epidermal growth factor receptor inhibitor
erlotinib, occurring in most patients receiving the drug. Clinical trials evaluating erlotinib for the treatment of
non-small cell lung cancer have reported a range of skin disorders, the most common being acneiform rash,
xeroderma (dry skin), pruritus, and paronychia. Although in the majority of cases these effects are mild and
transient, they can have a considerable impact on a patient’s quality of life and, if particularly severe and
persistent, may necessitate treatment interruption or cessation and compromise treatment outcome. This
coupledwith recent evidence to suggest a positive correlation between the incidence and severity of rash and
clinical outcome among erlotinib-treated patients with advanced or metastatic non-small cell lung cancer
highlights the importance of adequately managing epidermal growth factor receptor inhibitorerelated skin
disorders. Clear treatment strategies are therefore necessary to ensure the prevention and optimal manage-
ment of erlotinib-related skin toxicities thereby enabling patients to continue erlotinib treatment. In this
review we present a practical approach for the treatment of erlotinib-related cutaneous side effects in
Japanese patients with advanced non-small cell lung cancer providing details of specific treatment
interventions, according to symptom severity, for each of the common skin disorders. In addition, the
importance ofpreventive skin caremeasuresenamelymaintaining cleanliness,moisturization, andprotection
from external stimuliein preventing the development of serious skin disorders is discussed and guidelines for
the practice of proper skin care are presented. ( J Am Acad Dermatol 2013;69:463-72.)
Key words: acneiform rash; cutaneous side effects; epidermal growth factor receptor inhibitor; erlotinib;
Japanese patients; non-small cell lung cancer; prevention; skin toxicities.Abbreviations used:
ADL: activities of daily living
AEs: adverse events
BSA: body surface area
CI: confidence interval
CRC: colorectal cancer
EGFR: epidermal growth factor receptor
FTUs: fingertip units
HR: hazard ratio
NSCLC: non-small cell lung cancer
OS: overall survival
STEPP: Skin Toxicity Evaluation Protocol with
Panitumumab
UV: ultravioletI
n recent years, targeted therapy directed at the
epidermal growth factor receptor (EGFR) has
emerged as an important therapeutic option for
the treatment of patients with a range of solid tumors
including non-small cell lung cancer (NSCLC).
Erlotinib is a highly selective oral tyrosine kinase
inhibitor that targets EGFR to inhibit tumor cell
growth and proliferation.1 Based on the results of
1 international phase III study (BR.21) and 2
Japanese phase II studies, erlotinib monotherapy
has received regulatory approval in Europe, the
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failed at least 1 previous chemotherapy regimen.2-4
Dermatologic side effects are relatively common
among patients treated with EGFR inhibitors.5,6
These skin disorders are generally mild or moderate
in severity and can be managed by appropriate
interventions or by reducing or interrupting theCAPSULE SUMMARY
d Skin toxicities are a common side effect
of the epidermal growth factor receptor
inhibitor erlotinib.
d We present a practical approach for the
treatment of erlotinib-related cutaneous
side effects including treatment
interventions according to symptom
severity and the importance of
preventive measures.
d Skin toxicities impact quality of life and
may necessitate treatment interruption.
Ensuring the prevention and optimal
management of erlotinib-related skin
toxicities will enable erlotinib treatment
continuation to gain the best outcome.erlotinib dose. Appropriate
and timely management
make it possible to continue
a patient’s quality of life and
maintain compliance; how-
ever if these adverse events
(AEs) are not managed ap-
propriately, and become
more severe, treatment ces-
sation may be warranted
compromising clinical out-
come. Evidence has emerged
in recent years to suggest that
the incidence and severity of
rash are positively correlated
with treatment outcome
among patients receiving er-
lotinib (Fig 1).7-12 Strategies
to improve the assessment
and management of EGFR-
related skin AEs are therefore
essential to ensure compliance with anticancer ther-
apy, thereby enabling patients to achieve optimal
benefits. The purpose of this article is to describe the
most common erlotinib-related skin disorders in
patients with advanced/metastatic NSCLC and to
provide treatment strategies for their management.
ERLOTINIB-RELATED SKIN DISORDERS:
SYMPTOMS AND INCIDENCE
Common skin disorders with erlotinib
The most frequently occurring skin disorders re-
ported with erlotinib are acneiform rash, xeroderma
(dry skin), pruritus, and paronychia (periungual in-
flammation). Skin disorders have been generally cat-
egorized by the CommonTerminology Criteria for AEs
v4.0 (Table I),with special criteria forparonychiabeing
adopted because there is no Common Terminology
Criteria for AEs category for paronychia. Erlotinib-
related acneiform rash typically manifests as red pap-
ules and/or pustules on the face, chest, abdomen, or
thighs (Fig 2). Several featuresdistinguish anacneiform
rash from acne vulgaris, including the absence of
bacterial infection.13 Xeroderma is characterized by
dryness and roughness of the skin, and scaling (Fig 2).
The scales may be associated with inflammatory ery-
thema or pigmentation. As the condition progresses,
fissures appear and the skin becomes itchy and similarto pityriasis, resembling fish scales; the fissures can
cause considerable pain. Pruritus, or skin itching,
usually develops with xeroderma or dermatitis; it is
unusual for a patient to presentwith pruritus without a
rash. Pruritusmay cause patients to scratch, resulting in
scratch marks, lichenification, and eczematous inflam-
mation with hyperpigmentation and/or secondaryinfection. Paronychia mani-
fests as dusky erythema
around several fingernails
and toenails (Fig 3). This re-
sults in the formation of pain-
ful fissures, swelling, and
noninfectious granulation.
Bleeding or exudation can re-
sult in crust formation, which
may be extremely painful and
severely impact quality of life.
Secondary infection arising
fromparonychia is also a com-
mon problem.
Incidence of the most
common skin disorders
Data from a Japanese post-
marketing surveillance study
of erlotinib-treated patients
with NSCLC (POLARSTAR;n = 3488) revealed a high incidence of rash (63%),
with somewhat lower incidences for dry skin, pruri-
tus, and paronychia (7.7%, 3.8%, and 6.0%, respec-
tively).14 The majority of the skin disorders were
grade 1 (mild) or grade 2 (moderate) in severity; just
6.7% of rash caseswere grade 3 or higher, and 0.2% of
dry skin and pruritus episodes and 0.7% of paro-
nychia cases were grade 3 or higher in the surveil-
lance study (Table II).14,15
Time of onset typically varies according to the type
of skin disorder. In the POLARSTAR study, median
time to onset was shortest for rash (8 days, range
1-494) and longest for paronychia (32 days, range
2-558); median time to onset for dry skin and pruritus
were 15 days and 11 days, respectively (Table II).14
These findings are generally comparable with those
from the 2 phase II studies for rash (median 6 days),
pruritus (median 7 and 9 days), dry skin (12 and 23
days), and paronychia (41.5 and 49.5 days).16
TREATMENT STRATEGIES FOR
ERLOTINIB-RELATED RASH
Published evidence
Few randomized controlled trials have been
conducted in the management of EGFR-related
skin disorders; 5 have been published to date
although each study is small.17-21 The studies were
Fig 1. Rash emergence, severity, and survival. Relation-
ship between these in BR.21 study.11 CI, Confidence
interval; HR, hazard ratio. Reprinted from Clinical Cancer
Research 2007;13(13):3913-22, Wacker B et al, Correlation
between development of rash and efficacy in patients
treated with the epidermal growth factor receptor tyrosine
kinase inhibitor erlotinib in two large phase III studies,
with permission from AACR.
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range of EGFR inhibitors (cetuximab, panitumumab,
erlotinib, gefitinib) and investigated the use of pro-
phylactic or reactive treatments (Table III). Of these
studies, 2 generated positive findings.
Themost persuasive results were seen in the open-
label phase II Skin Toxicity Evaluation Protocol with
Panitumumab (STEPP) trial in patientswithmetastatic
colorectal cancer. Patients receiving therapy includ-
ing the EGFR inhibitor panitumumab were random-
ized to pre-emptive treatment (n = 48, comprising
emollients, sunscreen, topical steroid, and doxycy-
cline) or reactive treatment (n = 47) after skin toxicity
developed. Notably, the primary endpoint, the inci-
dence of specific grade 2 or higher skin toxicities
during the 6-week skin treatment period, was re-
duced by more than 50% in the pre-emptive group
compared with the reactive group (62% vs 29%; odds
ratio 0.3; 95% confidence interval 0.1-0.6) (Fig 4).21
In a randomized, double-blind trial of prophylactic
oral minocycline in patients withmetastatic colorectal
cancer, patients receiving cetuximab were random-
ized to receive oral minocycline 100 mg once daily or
placebo for the first 8 weeks of therapy. Up toweek 4,
mean lesion count in the oral minocycline group was
half that of theplacebogroup (P= .005),butbyweek8
the placebo group had spontaneously improved,
suggesting the effects of prophylactic oral minocy-
cline were most effective on early symptoms.17
Several reports into the use of topical retinoids in
the treatment of EGFR-induced skin disorders have
been published.22-26 One agent, adapalene (a topical
retinoid) has been used successfully to treat paro-
nychia in patients receiving EGFR inhibitors (gefitinib,erlotinib, cetuximab).25,26 In case studies of 4 patients
(1 with lung cancer receiving gefitinib, 1 with lung
cancer receiving erlotinib, and 2 with rectal cancer
receiving cetuximab) who had developed EGFR-
related paronychia of grade 2 or 3, administration of
adapalene gel for 2 to 4 weeks led to resolution of the
paronychia in each case.25,26 Adapalene was also
reported to reduce severe acneiform eruptions in a
cetuximab-treated patient with colorectal cancer.27
The observations to date provide an option for the
treatment of paronychia or acneiform rash when
other measures have not been effective.
Interventions by symptom severity
Taking the published reports into account, to-
gether with our experience in the Japanese clinical
context, we have compiled an algorithm (Fig 5) that
will support patients and physicians in the manage-
ment of their EGFR-related skin disorders. The algo-
rithm provides guidance for the diagnosis and
treatment of the 3 most common erlotinib-related
skin disorders: acneiform rash, xeroderma, and par-
onychia. Because such skin disorders are usually
aseptic, topical steroids and emollients are the main-
stay of treatment. However, if the skin disorder
persists, secondary infection may occur requiring
the use of antibiotics. Oral minocycline may be
prescribed with the expectation that it will have an
anti-inflammatory effect without infection during
grade 2. If a patient develops a grade 3 acneiform
rash, xeroderma, pruritus, or grade 2 or higher par-
onychia they should be referred to a dermatologist.
Five classes of topical steroid are currently mar-
keted in Japan based on their anti-inflammatory
potency: weak; medium; strong (eg, betamethasone
valerate/beclomethasone dipropionate); very strong
(eg, betamethasone butyrate/dexamethasone propi-
onate); and strongest (eg, clobetasol propionate and
diflorasone diacetate). Only topical steroids with a
potency ranking of strong or above are recommen-
ded for themanagement of erlotinib-related rash (Fig
5). Topical steroids are available as ointments,
creams, lotions, and tapes; choice of formulation
should be determined by the type of skin lesion.
Treatment should be initiated soon after the emer-
gence of a skin disorder and ongoing treatment may
be necessary for several weeks.
Emollients include oleaginous ointments (white
petroleum jelly), urea preparations, and heparinoids.
They should be applied after hand washing, and
immediately after showering or bathing, to suscep-
tible areas (eg, face, chest, and back) and to areas
that dry easily (eg, trunk, hands, and feet).
For both topical steroids and emollients, fingertip
units (FTUs) should be used as the guideline for the
Table I. Symptoms and interventions of most common erlotinib-related skin disorders by severity
Event Grade 1 Grade 2 Grade 3* Grade 4*
Acneiform
rash
Papules and/or pustules
covering\10% BSA, with/
without symptoms of
pruritus or tenderness
Papules and/or pustules covering 10%-30%
BSA, with/without symptoms of pruritus
or tenderness; associated with
psychosocial impact, and limiting
instrumental ADL
Papules/pustules covering[30%
BSA with/without symptoms of
pruritus or tenderness; limiting
self-care ADL associated with
local superinfection with oral
antibiotics indicated
Papules and/or pustules covering any
percent of BSA with/without symptoms
of pruritus or tenderness; associated with
extensive superinfection with IV
antibiotics indicated; life-threatening
consequences
Topical steroids (twice daily)
Face: medium/strong class
Other areas: strong class
Topical steroids
Face: strong class
Other areas: at least very strong
class 1 oral minocycliney (50 mg
twice daily)
Topical steroids
All areas: at least very strong
class 1 oral minocycliney 1 oral
steroids (prednisolone 10 mg
for 1 wk)
Refer for admission to major hospital
with dermatology specialists
Note: handling of cases such as Stevens-
Johnson syndrome or toxic epidermal
necrolysis requires specialist care
Grade 1 Grade 2 Grade 3*
Xeroderma
(dry skin)
Covering\10% BSA, without erythema
or pruritus
Covering 10%-30% BSA, with erythema or pruritus;
limiting instrumental ADL
Covering[30% BSA, with pruritus; limiting
self-care ADL
Emollients (heparinoids, petroleum jelly,
urea preparationsz)
Emollients 1 Topical steroids (at least strong class)
Pruritus Mild or localized; topical treatment
required
Intense or widespread; intermittent; skin changes
caused by scratching (eg, edema, papulation,
excoriations, lichenification, oozing/crusts); oral
intervention indicated; limiting instrumental ADL
Intense or widespread; constant; limiting
self-care ADL or sleep; oral corticosteroids
or immunosuppressants indicated
Emollients 1 topical steroids
(at least strong class)
Emollients 1 topical steroids (at least strong class) 1 oral antihistamines or oral antiallergy medicines
Paronychiax// Nailfold edema or erythema; disruption
of cuticle
Localized intervention indicated; oral intervention
indicated (eg, antibiotic, antifungal, antiviral);
nailfold edema or erythema with pain; associated
with discharge or nail plate separation; limiting
instrumental ADL
Surgical intervention or IV antibiotics
indicated; limiting self-care ADL
Washing 1 cooling{ 1 topical
steroids (at least strong
class) 1 emollients 1 taping
Washing 1 cooling 1 topical steroids (at least very
strong class) 1 emollients 1 taping or
cryotherapy (liquid nitrogen) 1 oral minocycline;
if there is fissuring, flurandrenolide tape
Washing 1 cooling
Grade 2 treatments/partial nail
removal/artificial nail placement
Skin disorders are graded according to Common Terminology Criteria for Adverse Events v4.0.13
ADL, Activities of daily living; BSA, body surface area; IV, intravenous.
*Refer to dermatologist promptly.
ySwitch to macrolide antibiotic if dizziness occurs.
zCan cause burning or stinging in areas with fissuring.
xIf grade $ 2 refer to dermatologist promptly.
//Paronychia severity is graded according to criteria prepared by editorial committee of Erlotinib Rash Management Overview and Specific Treatment Guidelines v3.0.
{Water or gel-type cooling agent should be used to cool entire area.
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Fig 2. Acneiform rash and xeroderma. Characteristic symptoms.
Fig 3. Paronychia. Characteristic symptoms.
Table II. Incidence and time to onset of most
common skin disorders in postmarketing
surveillance study of advanced non-small cell lung
cancer (analysis of 3488 patients in safety data set)14
Event
Incidence, % (n) Time to onset, d
All grades* Grade $ 3 Median (range)
Rash 63.0 (2199) 6.7 (234) 8 (1-494)
Dry skin 7.7 (270) 0.2 (8) 15 (1-185)
Pruritus 3.8 (132) 0.2 (6) 11 (1-220)
Paronychia 6.0 (210) 0.7 (23) 32 (2-558)
If patient experienced multiple events in same category, grade of
most serious episode was used.
*Common Terminology Criteria for Adverse Events v3.0.15
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to approximately 0.5 g for ointments and creams, or an
amount from the tip to the first joint of the index finger
(for a lotion, 1 FTU is about the size of a coin). One
FTU is a suitable amount for covering approximately 2
adult palms (Fig 6).28,29 Due to concerns regarding thedevelopment of adverse reactions with topical ste-
roids (eg, skin atrophy and telangiectasia), unneces-
sary long-term use of these agents should be avoided.
Acneiform rash
In the event of acneiform rash, strongor very strong
topical steroids, or in severe cases (grade 2/3) the
strongest class of topical steroids, should be applied
twice daily (Table I). Once symptoms have improved,
the patient should be switched to a medium-class
steroid. If symptoms worsen, the patient should be
switched to stronger-class steroids. Careful consider-
ation should be given to the degree of skin permea-
bility, and hence the level of drug absorption, of the
area of steroid application. Because the skin on the
face is highly permeable to steroid drugs, medium-
class steroids may be used for patients with a grade
1 acneiform rash on the face. In the case of grade 2 or
higher rash, the oral antibiotic minocycline should
also be given at a dose of 50 mg twice daily. Detailed
recommendations are also described in Table I.
Table III. Randomized controlled trials on management of epidermal growth factor receptor-related skin
disorders
Study EGFR inhibitor Tumor type Treatment Results
Scope et al,17 2007 Cetuximab CRC Prophylactic oral minocycline
100 mg od vs placebo for
8 wk
Decreased mild/moderate
lesion count with
minocycline at wk 4
(P = .005)
Prophylactic tazarotene 0.05%
od on left or right side of face
for 8 wk
No difference between groups
Jatoi et al,18 2008 Various Various Prophylactic oral tetracycline
500 mg bd vs placebo for
4 wk
Decrease in grade 2 rash with
tetracycline at wk 4 (P = .01);
no difference between
groups at wk 8 (P = .61)
Scope et al,19 2009 Cetuximab CRC Reactive topical pimecrolimus
1% bd for 5 wk on left or
right sides of face vs no
pimecrolimus
Greater decrease in lesion
count with pimecrolimus
(P\ .05)*
Jatoi et al,20 2010 Various Various Sunscreen (SPF 60) bd vs
placebo for 28 d
No difference between
treatment groups (P = .36)
Lacouture et al,21 2010 Panitumumab CRC Prophylactic treatmenty vs
reactive treatmentz
Decrease in grade $ 2 skin
toxicity with prophylaxis
(29% vs 62%)
bd, Twice a day; CRC, colorectal cancer; od, daily; SPF, sun protection factor.
*Lesions on both sides of face decreased significantly over study duration, therefore effect was considered not clinically relevant.
yIncluding skin moisturizer, sunscreen, topical steroid, and oral doxycycline.
zAny treatment as determined by physician.
Fig 4. Grade $ 2 skin toxicity in patients with metastatic
colorectal cancer (Skin Toxicity Evaluation Protocol with
Panitumumab [STEPP] study), time to first occurrence.21
CI, Confidence interval; NR, not reached. Reprinted from
Lacouture ME et al, Skin toxicity evaluation protocol with
panitumumab (STEPP), a phase II open-label, randomized
trial evaluating the impact of a pre-emptive skin treatment
regimen on skin toxicities and quality of life in patients
with metastatic colorectal cancer, Journal of Clinical On-
cology 28(8):1351-7, with permission.  (2010) American
Society of Clinical Oncology. All rights reserved.
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Erlotinib-related xeroderma should be treated
with emollients, with the addition of a topical steroid
(at least strong class) for grade 2 severity or higher
(Table I). Patients should be switched to a medium-
class topical steroid once symptoms improve.
Emollients should be used as soon as possible after
bathing to prevent the rapid development of dry skin
caused by washing away sebum.
Pruritus
If a patient experiences intense pruritus with an
acneiform rash or xeroderma, then emollients plus
topical steroids (at least strong class) should be
prescribed. Oral antihistamines or oral antiallergy
drugs should be used in addition to emollients
and steroids for pruritus of grade 2 severity or
higher.
Paronychia
The affected area should be washed with soapy
water, rinsed well, moisturized, and protected with
gauze (Table I). Additional benefit may be provided
by cooling the affected area using water or a gel-type
cooling agent, taping the affected area using stretch-
able tape (Fig 7), and applying emollients. Strong or
very strong topical steroids plus oral minocycline
Fig 5. Erlotinib-related skin disorders. Diagnosis and treatment.
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erythema may respond to treatment with just a
topical steroid (at least strong class). Treatment
recommendations for granulation include the stron-
gest class of topical steroids, oral minocycline, or
cryotherapy using liquid nitrogen. In severe cases,
surgical treatment involving removal of part of the
nail plate is needed (Fig 8). If the patient has a
comorbid bacterial infection oral minocycline
should be used.
Discontinuation or dose adjustment of
erlotinib
Based on experience with erlotinib2-4 we pro-
posed specific recommendations for the discontin-
uation or dose adjustment of erlotinib in patientsexperiencing skin toxicities (Table IV). Erlotinib
should be continued at a dose of 150 mg/d for
patients experiencing a grade 1 event. This is also
the case for grade 2 events unless symptoms do not
resolve on symptomatic therapy; in this situation
consideration should be given to dose reduction
(100 mg/d). Grade 3 skin toxicity requires dose
reduction to 50 mg/d; however, treatment inter-
ruption should be considered if there is no im-
provement after the use of potent symptomatic
therapy (eg, increasing the dose of topical steroid).
If the AE improves to grade 2 or lower, then
treatment with erlotinib may be resumed at 100
mg/d. Any patient experiencing grade 4 skin tox-
icity should permanently discontinue erlotinib
therapy.
Fig 6. Application of topical creams and emollients: guidance on quantities for application.
FTU, Fingertip unit.
Fig 7. Procedure for using tape to treat paronychia.
Fig 8. Procedure for removing nail plate and matrix in cases of paronychia.
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PATIENT EDUCATION
When initiating erlotinib therapy it is important to
explain to the patient that skin disorders often
develop during treatment and that if they experience
any skin abnormalities, including on the scalp or
around the nails, they should seek prompt medical
attention. Preventive skin care may reduce the inci-
dence, and prolong time to onset, of above grade 2
skin disorders and may also reduce severe skin
toxicity. This theory is supported by data from the
phase II STEPP trial in patients with metastatic
colorectal cancer, as described earlier.21
These findings emphasize the importance of ini-
tiating proper skin care in parallel with drug treat-
ment and continuing this on an ongoing basis to
mitigate the development of serious skin symptomsand enable continuation of therapy. All patients
should receive appropriate instruction in the funda-
mentals of proper skin care, which include main-
taining cleanliness, moisturization, and protection
from external stimuli. Patients should shower or
bathe every day using soaps and shampoos that are
relatively nonirritating (ie, weakly acidic) and using
the quantities indicated on the label; bath salts or
additives that contain sulfur are not recommended
because they can dry out the skin. The soap should
be worked into a good lather (which aids easier dirt
removal and is less irritating to the skin) and used to
gently wash the skin using the palm of the hand. Any
soap or shampoo should be thoroughly rinsed.
Drying should be by patting (not rubbing) gently
with a clean towel. If a patient experiences severe
itchiness they should bath or shower using water that
Table IV. Recommendations for dose adjustment of erlotinib after emergence of skin disorder
Grade 1 Grade 2 Grade 3 Grade 4
Continue
at 150 mg
Continue at 150 mg; if patient’s
condition worsens even with
symptomatic treatment (eg, steroid
therapy), consider reducing dose to
100 mg
Reduce dose to 50 mg; if
improvement is not seen despite
more powerful symptomatic
therapy, consider interrupting
treatment; if event falls to grade
# 2 in severity, treatment may be
resumed at 100 mg
Permanently discontinue
therapy
If treatment was initiated at 100 mg or 50 mg, consideration should be given to reducing dose or interrupting treatment as appropriate.
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and 398C in the winter). The education of male
patients may be particularly challenging as some
men may have a tendency to be unconcerned with
skin care, therefore important information should
also be given to their family members. The vast range
of skin care products marketed today makes it vital
that patients receive specific instruction on which
products to use and how to use them.
In addition to maintaining skin cleanliness and
moisturization it is sensible that patients protect their
skin from the sun to avoid ultraviolet (UV). Although
Jatoi et al found that there were no differences
between treatment groups in the use of sunscreen,20
there have been reports of individuals whose rash is
triggered or exacerbated by UV exposure,27 there-
fore sunscreen protection is a sensible precaution.
UV protection requires use of a high-factor sun-
screen (sun protection factor $ 30 and UVA protec-
tion grade of at least 11), which should be applied
liberally if going outside for an extended period. A
sunscreen that is labeled as ‘‘nonchemical’’ and does
not contain UV absorbers is recommended as these
ingredients can be irritants. Additional tips for
avoiding exposure to UV include wearing/using
clothing that blocks UV (eg, umbrellas, wide-
brimmed hats, sun visors, scarves, gloves, sun-
glasses, and clothing with few exposed areas).
In addition to understanding the importance of
preventive skin care, it is crucial that patients appre-
ciate the importance of using the appropriate doses
of topical treatments, particularly steroids. As already
discussed, the patient should be educated in the use
of FTUs as a guide to the amount of drug that should
be used per application (Fig 6).29,30CONCLUSION
Erlotinib is an important therapy for patients with
locally advanced or metastatic NSCLC, achieving a
significant overall survival benefit when used as
second- or third-line treatment. Although generally
well tolerated, erlotinib, in commonwith other EGFR
inhibitors, is associated with the development ofclass-specific cutaneous side effects, which appear to
be a surrogate marker for clinical outcome. The
mainstay of treatment for the most common skin
disorders associated with erlotinibenamely acnei-
form rash, xeroderma, pruritus, and paronychiaeis
topical steroids (at least strong class) together with
emollients. For patients with paronychia, adapalene
is also an option, having been effective for some
patients in the treatment of periungual inflammation.
Ultimately, by following the management and treat-
ment strategies for erlotinib-related skin toxicities
discussed in this review, continuation of erlotinib
treatment should be possible for a higher proportion
of patients, enabling them to benefit from this
promising therapy.
We thank Kiyoko Ogino, Chugai Pharmaceutical Co
Ltd, for useful discussion.
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